However, we found that patients with HR and TP53 co-mutations had a significantly increased risk of tumor recurrence (Figure 1D), suggesting a possible collaborative function between the loss of HR and p53 in promoting breast tumorigenesis. Here, TP53 is linked to neoplasm.